GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virios Therapeutics Inc (NAS:VIRI) » Definitions » Pretax Margin %

Virios Therapeutics (Virios Therapeutics) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Virios Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Virios Therapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was $-1.29 Mil. Virios Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Virios Therapeutics's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Virios Therapeutics's Pretax Margin % or its related term are showing as below:


VIRI's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.52
* Ranked among companies with meaningful Pretax Margin % only.

Virios Therapeutics Pretax Margin % Historical Data

The historical data trend for Virios Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virios Therapeutics Pretax Margin % Chart

Virios Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial - - - - -

Virios Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Virios Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Virios Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virios Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virios Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Virios Therapeutics's Pretax Margin % falls into.



Virios Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Virios Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-5.296/0
= %

Virios Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-1.291/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Virios Therapeutics  (NAS:VIRI) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Virios Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Virios Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Virios Therapeutics (Virios Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
44 Milton Avenue, Alpharetta, GA, USA, 30009
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.
Executives
William Pridgen director 44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan director, officer: Chief Executive Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh officer: VP of Finance 44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel director 44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer director 44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald officer: Vice President of Operations 44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau officer: Chief Medical Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch director 44 MILTON AVENUE, ALPHARETTA GA 30009